陈锦燕, 施玮, 庞红. 2005—2016年上海市长宁区卡介苗疑似预防接种异常反应的发生特征[J]. 上海预防医学, 2019, 31(4): 255-258. DOI: 10.19428/j.cnki.sjpm.2019.19320
引用本文: 陈锦燕, 施玮, 庞红. 2005—2016年上海市长宁区卡介苗疑似预防接种异常反应的发生特征[J]. 上海预防医学, 2019, 31(4): 255-258. DOI: 10.19428/j.cnki.sjpm.2019.19320
CHEN Jin-yan, SHI Wei, PANG Hong. Monitoring the adverse events following immunization of Bacillus Calmette-Guérin vaccine in Changning District of Shanghai, 2005-2016[J]. Shanghai Journal of Preventive Medicine, 2019, 31(4): 255-258. DOI: 10.19428/j.cnki.sjpm.2019.19320
Citation: CHEN Jin-yan, SHI Wei, PANG Hong. Monitoring the adverse events following immunization of Bacillus Calmette-Guérin vaccine in Changning District of Shanghai, 2005-2016[J]. Shanghai Journal of Preventive Medicine, 2019, 31(4): 255-258. DOI: 10.19428/j.cnki.sjpm.2019.19320

2005—2016年上海市长宁区卡介苗疑似预防接种异常反应的发生特征

Monitoring the adverse events following immunization of Bacillus Calmette-Guérin vaccine in Changning District of Shanghai, 2005-2016

  • 摘要:
    目的分析上海市长宁区卡介苗(Bacillus Calmette-Guérin vaccine, BCG)接种后疑似预防接种的异常反应(adverse events following immunization, AEFI)的发生特征,为其监测、诊断、鉴定和处理提供参考。
    方法通过上海市AEFI监测数据库和中国免疫规划信息管理系统收集长宁区2005—2016年报告的BCG接种后AEFI个案信息,采用描述性流行病学方法进行统计分析。
    结果2005—2016年,长宁区报告BCG接种后AEFI共34例,报告发生率为20.02/10万剂次,其中异常反应30例,报告发生率为17.67/10万剂次。异常反应以BCG淋巴结炎18例(60.00%,10.60/10万剂次)和局部脓肿11例(36.67%,6.48/10万剂次)为主,全身播散性BCG感染报告1例。
    结论长宁区BCG安全性在预期范围内,2005—2016年AEFI报告发生率变化不明显,异常反应以BCG淋巴结炎和局部脓肿为主。

     

    Abstract:
    ObjectiveTo analyze characteristics of adverse events following immunization (AEFIs) with Bacillus Calmette-Guérin vaccine (BCG) during 2005-2016 in Changning District, Shanghai, and to evaluate the safety of BCG vaccination and the AEFI, providing reference for its monitoring, diagnosis, identification and management.
    MethodsThe AEFI case data related to BCG immunization from Shanghai AEFI reporting registry and the National AEFI Surveillance System during 2005-2016 were collected for descriptive epidemiological analyses.
    ResultsA total of 34 BCG AEFIs were reported during 2005-2016 in Changning District, incidence rate being 20.02 per 100 000 doses.Among the AEFIs reported, 30 (17.67 per 100 000 doses) were rare adverse reactions.Among rare adverse reactions, 18 (60.00%, 10.60 per 100 000 doses) were BCG lymphadenitis, and 11 (36.67%, 6.48 per 100 000 doses) were local abscess.One case was identified as disseminated BCG infection.
    ConclusionThe BCG safety profile is consistent with expectations.The incidence of BCG AEFIs do not change significantly during 2005-2016.The most common rare adverse reactions are BCG lymphadenitis and local abscess.

     

/

返回文章
返回